U.S. Stock News

Why OGE Energy Is On Investors’ Radar OGE Energy (OGE) has come into focus after a recent move in its share price, with the stock last closing at $48.41. This has prompted investors to reassess how its current valuation lines up with its fundamentals. See our latest analysis for OGE Energy. For context, the recent share price move to $48.41 sits on top of an 11.88% 1 month share price return and a 12.90% year to date share price return, while total shareholder return sits at 10.76% over one...

Latest FY 2025 Results: Revenue Rebound and Margins Back in Focus UWM Holdings (UWMC) has wrapped up FY 2025 with fourth quarter revenue of US$759.0 million and basic EPS of US$0.08, while trailing twelve month revenue came in at US$2.4 billion with basic EPS of US$0.13. The company has seen quarterly revenue range from US$613.4 million to US$967.6 million across 2025, with EPS swinging between a loss of US$0.08 in Q1 and a profit of US$0.11 in Q2 before landing at US$0.08 in Q4. Over the...

Fidelity National Information Services (FIS) just closed out FY 2025 with Q4 revenue of US$2.8 billion and basic EPS of US$0.99, alongside net income of US$511 million that puts a clear spotlight on how the business is earning each dollar. The company has seen quarterly revenue move from US$2.6 billion and EPS of US$0.15 in Q1 2025 to US$2.8 billion and EPS of US$0.99 in Q4, with trailing twelve month EPS of US$0.73 on revenue of US$10.7 billion framing the broader trend. For investors, the...

Why Silicon Laboratories Is On Investors’ Radar Today Silicon Laboratories (SLAB) has caught investor attention after a sharp move in its share price over the past month, with the stock returning about 45% over that period. See our latest analysis for Silicon Laboratories. That recent 45.2% 30 day share price return and 61.9% 90 day share price return stand out against a 43.1% total shareholder return over the past year. This suggests momentum has picked up after a quieter stretch. If Silicon...

In February 2026, ARMOUR Residential REIT, Inc. reported full-year 2025 results showing net income of US$322.69 million and basic earnings per share from continuing operations of US$3.31, alongside declaring a US$0.24 per-share cash dividend payable on March 30, 2026 to shareholders of record on March 16, 2026. The swing from a prior-year net loss and loss per share to positive earnings highlights a material turnaround in ARMOUR Residential REIT’s profitability profile. Next, we’ll examine...

In mid-February 2026, Lockheed Martin announced a major foreign military sale to supply C-130J training devices and upgrades to the Royal Australian Air Force, alongside agreements with the U.S. government to significantly expand THAAD and PAC-3 missile interceptor production. Together with management’s projections for 2026 revenue and profit above Wall Street estimates, these contracts highlight how government partnerships can influence Lockheed Martin’s long-term earnings profile and...

Enovix recently reported past fourth-quarter results that surpassed expectations, pointing to stronger-than-anticipated operational execution in its battery business. This outperformance, set against a backdrop of cautiously neutral analyst ratings, highlights a gap between reported progress and still‑measured market expectations. With this stronger quarterly performance now on the table, we’ll examine how it interacts with Enovix’s high-volume manufacturing and diversification...

Cytokinetics (CYTK) has capped FY 2025 with Q4 revenue of US$17.8 million and a basic EPS loss of US$1.52, anchored by a net loss of US$183.0 million. This sets the tone for how investors are reading the latest update against a year of heavy spending. Over recent periods, the company has seen quarterly revenue range from US$1.6 million to US$66.8 million in FY 2025, while basic EPS losses have moved between US$1.12 and US$2.55. This gives a clear picture of a business that is still investing...

LTC Properties FY 2025 Earnings Snapshot LTC Properties (LTC) has wrapped up FY 2025 with fourth quarter total revenue of US$84.3 million and basic EPS of US$2.13, supported by funds from operations of US$34.5 million and FFO per share of US$0.72, alongside trailing 12 month EPS of US$2.54 on revenue of US$262.9 million. Over recent periods, the company has seen total revenue move from US$51.9 million in Q4 2024 to US$84.3 million in Q4 2025, while basic EPS shifted from US$0.40 in Q4 2024 to...

If you are wondering whether Expedia Group's share price reflects its real worth today, you are not alone. This article will walk through what the current market price might be implying about the company. After a long term return of 93.5% over 3 years and 25.7% over 5 years, the stock has recently pulled back, with a 24.4% decline over 30 days and a 28.0% decline year to date from a last close of US$203.74. This may have shifted how the market is thinking about its future. Recent headlines...

Acadia Healthcare Company (ACHC) just wrapped up FY 2025 with Q4 revenue of US$821.5 million and a basic EPS loss of US$13.02, alongside a trailing 12-month basic EPS loss of US$12.16 on revenue of about US$3.3 billion. The company has seen quarterly revenue move from US$774.2 million in Q4 2024 to US$770.5 million in Q1 2025, US$869.2 million in Q2, US$851.6 million in Q3, and US$821.5 million in Q4, while basic EPS shifted from US$0.36 in Q4 2024 to US$0.09, US$0.33, and US$0.40 through the...

If you are wondering whether Repligen's current share price lines up with its underlying worth, you are not alone. This article walks through what the numbers actually say about value. Repligen's share price closed at US$132.14, with returns of a 4.3% decline over 7 days, 19.1% decline over 30 days, 19.6% decline year to date, 18.8% decline over 1 year, 25.1% decline over 3 years, and 33.9% decline over 5 years. This may signal that expectations or perceived risk have shifted over...

Talos Energy FY 2025 earnings recap Talos Energy (TALO) closed out FY 2025 with fourth quarter revenue of US$392.2 million and a basic EPS loss of US$1.19, alongside a full year trailing twelve month revenue base of about US$1.8 billion and a loss of US$2.82 per share. Over recent quarters, the company has seen quarterly revenue move from US$509.1 million in Q3 2024 to US$512.9 million in Q1 2025 and then within a US$392.2 million to US$450.0 million range through Q4 2025. Basic EPS shifted...

CleanSpark (CLSK) moved into focus after its latest quarterly report, where a wider-than-expected net loss coincided with management spotlighting a shift toward high-performance computing and AI infrastructure tied to new data center leases. See our latest analysis for CleanSpark. The share price reaction around the recent earnings and AI data center update comes against a mixed backdrop. There has been a 12.73% 7-day share price return, but a 16.00% 30-day and 22.30% 90-day share price...

Tri Pointe Homes (TPH) just posted its FY 2025 numbers with fourth quarter revenue of US$972.6 million and basic EPS of US$0.71, alongside full year trailing twelve month revenue of US$3.5 billion and EPS of US$2.73. Over the past six quarters, revenue has moved from US$1.25 billion in Q4 2024 to US$972.6 million in Q4 2025, while quarterly EPS shifted from US$1.39 to US$0.71. Investors now have to weigh these results against a trailing net margin that sits at 6.9% compared with 10.2% a year...

Himax Technologies (HIMX) has put fresh numbers on the table, reporting fourth quarter 2025 revenue of US$203.08 million and net income of US$6.34 million, alongside softer full year results and cautious first quarter 2026 guidance. See our latest analysis for Himax Technologies. The latest results and cautious first quarter 2026 outlook come after a mixed share price pattern, with a 7 day share price return of 3.0% and a 90 day share price return of 4.12% contrasted by a 1 year total...

Adient (ADNT) has drawn fresh attention after introducing Sculpted Soft Trim, a new seat trim product aimed at improving vehicle interior design, cutting sewing labor, and simplifying complex shapes for automaker customers. See our latest analysis for Adient. The Sculpted Soft Trim launch comes as Adient’s share price sits at US$24.79, with a 30 day share price return of 16.06% and a year to date share price return of 30.20%. This points to building momentum despite a 3 year total shareholder...

Ares Management (NYSE:ARES) has appointed Michael Harper as head of portfolio management for systematic credit. The move comes as private credit faces increased scrutiny around liquidity risks after Blue Owl Capital imposed withdrawal restrictions. Investors are watching how large alternative asset managers respond to liquidity concerns across their private credit offerings. Ares Management, trading at $119.18, sits at the center of the conversation on private credit given its scale and...

InfuSystem Holdings (INFU) has wrapped up FY 2025 with Q4 revenue of US$36.2 million and basic EPS of US$0.10, capping a year in which trailing twelve month revenue reached US$143.4 million and EPS came in at US$0.32. The company has seen quarterly revenue move from US$33.8 million in Q4 2024 to US$36.5 million in Q3 2025 and US$36.2 million in Q4 2025, while basic EPS shifted from US$0.04 in Q4 2024 through a low of US$0.01 loss in Q1 2025 before landing between US$0.10 and US$0.12 over the...

Clear Secure FY 2025 earnings snapshot Clear Secure (YOU) has wrapped up FY 2025 with fourth quarter revenue of US$240.8 million and basic EPS of US$0.31, alongside trailing 12 month revenue of US$900.8 million and EPS of US$1.14 that frame the latest print in a broader earnings context. Over recent periods the company has seen quarterly revenue move from US$198.4 million in Q3 2024 to US$240.8 million in Q4 2025, while basic EPS has shifted from US$0.25 to US$0.31 across the same span...

In February 2026, Amphastar Pharmaceuticals received U.S. FDA approval for its Ipratropium Bromide HFA Inhalation Aerosol as a generic equivalent to Boehringer Ingelheim's Atrovent HFA, including 180 days of marketing exclusivity for COPD maintenance treatment. This short period of exclusivity offers Amphastar a time-limited window to build presence in the inhaled COPD market while supporting its broader mix of generic and proprietary products. Next, we’ll examine how the 180-day exclusivity...

AbbVie (NYSE:ABBV) is committing $380 million to build two advanced manufacturing facilities in the U.S. for neuroscience and obesity medicines. The new sites are expected to support next generation production using artificial intelligence and create about 300 jobs. AbbVie also received FDA approval for the first all oral, fixed duration combination regimen for chronic lymphocytic leukemia. For a company already known for its immunology and oncology portfolio, these two moves mark a...

Life Time Group Holdings (LTH) closed out FY 2025 with Q4 revenue of US$745.1 million, basic EPS of US$0.56 and net income excluding extra items of US$123 million, set against a year in which trailing twelve month revenue reached US$3.0 billion, EPS was US$1.71 and net income was US$373.7 million. Over the past few quarters, the company has seen revenue move from US$663.3 million and EPS of US$0.18 in Q4 2024 to US$745.1 million and EPS of US$0.56 in Q4 2025. Trailing EPS stepped up from...

UFP Technologies (UFPT) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and basic EPS of US$2.28, framed by trailing twelve month revenue of US$602.8 million and EPS of US$8.87 that reflect earnings growth of 15.8% over the past year. The company has seen revenue move from US$504.4 million and EPS of US$7.69 on a trailing basis in Q4 2024 to US$602.8 million and EPS of US$8.87 by Q4 2025, which sets the scene for investors to weigh solid earnings expansion against a slightly softer...